Financial News

Everest Starts China Phase III Trial of Ulcerative Colitis Treatment

Everest Medicines, a New York biopharma that develops novel drugs for Greater China and Asia, has dosed the first patient in a China Phase III trial of etrasimod, a novel treatment for ulcerative colitis. In 2017, Everest in-licensed greater China rights to etrasimod from Arena Pharma of San Diego in a $224 million two-drug agreement. Everest was backed with $50 million in initial financing led by China's C-Bridge Capital and set up as a C-Bridge incubator platform for bringing novel drugs to China. More details.... Stock Symbol: (NSDQ: ARNA) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback